Skip to main content
. 2018 Mar 26;8(5):647–652. doi: 10.3892/mco.2018.1595

Figure 2.

Figure 2.

Five-year overall survival rates in the LAMA/LABA group and the LAMA group. Differences in overall survival between the two groups were analyzed using log-rank tests. LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist.